PeproMene Bio, Inc. and IFLI announce $11M Investment

PeproMene Bio, Inc. has announced an $11M investmentfrom the Institute for Follicular Lymphoma Innovation (IFLI)to support the clinical development of...

Innate Pharma and IFLI announce up to $7.9M investment

Innate Pharma SA, together with the Institute for Follicular Lymphoma (IFLI), today announced that they have...

IFLI Announces $2.1 M in funding for research

The Institute for Follicular Lymphoma Innovation (IFLI) today announced $2.1 million in funding for a four year research collaboration with Washington...

IFLI Announces Additional Recipients of Idea Award

The Institute for Follicular Lymphoma Innovation (IFLI) proudly announces additional recipients of its Idea Award. This award is a key component of...

IFLI Sponsors Women in Lymphoma’s Webinar Series

The Institute for Follicular Lymphoma Innovation (IFLI) is proud to announce its sponsorship of Women in Lymphoma’s (WiL) upcoming...

IFLI Joins California Life Sciences

IFLI is proud to announce its new membership with California Life Sciences (CLS), a prestigious organization dedicated to advancing...

$2.25 Million for Three Promising Research Projects

The Follicular Lymphoma Foundation (FLF), The Leukemia & Lymphoma Society (LLS) and the Institute for Follicular Lymphoma Innovation (IFLI)...

Announcing $2 Million Research Program

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, and Institute for Follicular...

Introducing The New RAFL Program

The Institute for Follicular Lymphoma Innovation (IFLI) and The Leukemia & Lymphoma Society (LLS) have joined forces in a strategic partnership...

New $20 Million Research Program

The Leukemia & Lymphoma Society (LLS) and Institute for Follicular Lymphoma Innovation (IFLI) today announce a new partnership...

IFLI Announces Recipients of Prestigious Idea Award

The Institute for Follicular Lymphoma Innovation (IFLI), a global, multi-arm, non-profit, private foundation committed to accelerating the...

Lysa-Lysarc and IFLI Launch BIDIFLY

The LYSA-LYSARC cooperative group, an international leader in basic, translational and clinical research on lymphomas, and the Institute for Follicular Lymphoma...